Neurologic Disorders Therapeutics Strategic Business Report 2023-2030: Development of Precision Medicine and Targeted Therapies Strengthens Business Case

MLA

“Neurologic Disorders Therapeutics Strategic Business Report 2023-2030: Development of Precision Medicine and Targeted Therapies Strengthens Business Case.” Plus Company Updates, 30 Oct. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.814134614&authtype=sso&custid=ns315887.

APA

Neurologic Disorders Therapeutics Strategic Business Report 2023-2030: Development of Precision Medicine and Targeted Therapies Strengthens Business Case. (2024, October 30). Plus Company Updates.

Chicago

Plus Company Updates. 2024. “Neurologic Disorders Therapeutics Strategic Business Report 2023-2030: Development of Precision Medicine and Targeted Therapies Strengthens Business Case,” October 30. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.814134614&authtype=sso&custid=ns315887.